Dataset from A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)

The purpose of this study is to assess the efficacy and safety of daily treatment with Dexlansoprazole modified release (MR) (60 mg or 90 mg once daily [QD]) compared to placebo QD in relief of daytime and nighttime heartburn over 4 weeks in subjects with gastroesophageal reflux disease (GERD).

本研究旨在评估每日服用右兰索拉唑缓释（Modified Release，MR）制剂（60mg或90mg，每日一次[QD]）与每日一次安慰剂对照，在为期4周的周期内缓解胃食管反流病（GERD）受试者日间与夜间烧心症状的有效性与安全性。